The author argues that a remarkably large investor has fully exited their SLS position, with rumors that another prominent holder has also sold. This whale exodus is presented as evidence that the probability of the company's failure is now a major concern, a risk the author says is already reflected in the falling share price. The main stated risk is the underlying clinical/financial failure of the company itself.